Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval

Yusimry Biosimilar To Humira Set For 1 July 2023 Launch, After Multiple Rivals

 
• By Dave Wallace
  
Alarm clock dollar bills money
Coherus must wait until mid-2023 to make its “compelling value proposition” • Source: Alamy

More from Biosimilars

More from Products